Legal & General Group Plc Acquires 9,528 Shares of BioNTech SE Sponsored ADR $BNTX

Legal & General Group Plc boosted its holdings in BioNTech SE Sponsored ADR (NASDAQ:BNTX) by 3.1% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 321,111 shares of the company’s stock after acquiring an additional 9,528 shares during the period. Legal & General Group Plc owned 0.14% of BioNTech worth $30,636,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also added to or reduced their stakes in the business. Leonteq Securities AG bought a new stake in BioNTech in the 4th quarter valued at $2,609,000. Larson Financial Group LLC raised its stake in BioNTech by 86.4% in the 4th quarter. Larson Financial Group LLC now owns 274 shares of the company’s stock valued at $26,000 after acquiring an additional 127 shares during the period. ProShare Advisors LLC increased its position in BioNTech by 24.6% during the 4th quarter. ProShare Advisors LLC now owns 4,464 shares of the company’s stock worth $425,000 after buying an additional 880 shares during the period. HighTower Advisors LLC increased its position in BioNTech by 30.6% during the 4th quarter. HighTower Advisors LLC now owns 21,234 shares of the company’s stock worth $2,021,000 after buying an additional 4,971 shares during the period. Finally, Privium Fund Management B.V. increased its position in BioNTech by 75.3% during the 4th quarter. Privium Fund Management B.V. now owns 33,300 shares of the company’s stock worth $3,170,000 after buying an additional 14,300 shares during the period. Institutional investors own 15.52% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the company. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of BioNTech in a research report on Tuesday, March 17th. Raymond James Financial reiterated an “outperform” rating on shares of BioNTech in a research report on Tuesday, March 10th. Bank of America reiterated a “buy” rating and set a $128.00 price objective on shares of BioNTech in a research report on Tuesday, March 10th. Weiss Ratings reiterated a “sell (d-)” rating on shares of BioNTech in a research report on Wednesday, April 8th. Finally, Jefferies Financial Group reiterated a “buy” rating on shares of BioNTech in a research report on Wednesday, March 25th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, BioNTech presently has an average rating of “Moderate Buy” and an average price target of $129.56.

Insider Activity

In other news, COO Sierk Poetting sold 50,000 shares of the stock in a transaction on Wednesday, April 22nd. The stock was sold at an average price of $110.56, for a total transaction of $5,528,000.00. Following the sale, the chief operating officer directly owned 399,387 shares of the company’s stock, valued at approximately $44,156,226.72. This represents a 11.13% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 19.20% of the company’s stock.

BioNTech Stock Performance

BNTX opened at $95.95 on Friday. The firm has a market cap of $24.26 billion, a P/E ratio of -16.32 and a beta of 1.36. BioNTech SE Sponsored ADR has a 52-week low of $79.52 and a 52-week high of $124.00. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.74 and a current ratio of 8.80. The business’s fifty day moving average is $94.46 and its 200-day moving average is $99.49.

BioNTech (NASDAQ:BNTX) last released its earnings results on Saturday, February 14th. The company reported ($0.39) earnings per share (EPS) for the quarter. The company had revenue of $1.06 billion for the quarter. BioNTech had a negative return on equity of 5.30% and a negative net margin of 44.39%. Sell-side analysts expect that BioNTech SE Sponsored ADR will post -4.71 EPS for the current fiscal year.

BioNTech announced that its board has initiated a stock repurchase program on Thursday, May 7th that authorizes the company to buyback $1.00 billion in outstanding shares. This buyback authorization authorizes the company to repurchase up to 4.2% of its shares through open market purchases. Shares buyback programs are generally an indication that the company’s board believes its stock is undervalued.

About BioNTech

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.